GENMAB A/S -SP ADR (GMAB)
US3723032062 - ADR
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
Genmab is buying a privately held company focused on antibody drug conjugates.
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
AbbVie/ Genmab win FDA priority review for lymphoma therapy (NYSE:ABBV)
Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.
BMO upgrades Genmab to outperform, cites diversification potential (NASDAQ:GMAB)
BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term
Genmab reports FY results (NASDAQ:GMAB)
Genmab reports a FY operating profit of DKK 5,321 million in 2023, with revenue reaching DKK 16.47B, driven by successful collaborations and strong product...
Pfizer-Genmab cervical cancer drug gets accepted for EU review (NYSE:PFE)
Pfizer (PFE) and Genmab (GMAB) announced on Friday the marketing application for its cervical cancer antibody-drug conjugate ((ADC)) has been validated for revi
J&J seeks expanded FDA approval of Darzalex Faspro for multiple myeloma (NYSE:JNJ)
Johnson & Johnson (JNJ) said that it has submitted a supplemental Biologics License Application for approval of a Darzalex Faspro-based regimen for the treatmen
Genmab Enters Oversold Territory (GMAB)
Johnson & Johnson wins arbitration appeal against Genmab
Genmab (GMAB) loses appeal in arbitration with J&J (JNJ) over multiple myeloma therapy Darzalex Faspro, but it won't impact the company's 2024 guidance. Read more here.
Pfizer, Genmab cancer therapy under FDA priority review
Pfizer (PFE) and Genmab's (GMAB) cervical cancer therapy, Tivdak, has received priority review from the FDA for full approval. Read more here.
FDA’s new drug approvals for 2023 rise 51% from last year
The U.S. FDA's Center for Drug Evaluation and Research (CDER) has licensed 56 novel treatments in 2023, a 51% increase from 2022. Read more here.
FDA’s new drug approvals for 2023 rise 51% from last year (NYSE:PFE)
The U.S. FDA's Center for Drug Evaluation and Research (CDER) has licensed 56 novel treatments in 2023, a 51% increase from 2022. Read more here.
JNJ multiple myeloma therapy outperforms standard of care (NYSE:JNJ)
Johnson & Johnson's (JNJ) multiple myeloma therapy Darzalex Faspro in combination with traditional treatments outperforms standard of care. Read more here.